The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI Corporation has received a waiver from the UK's MHRA, exempting its product Multikine from pediatric evaluation for head and neck cancer treatment in the UK.
September 04, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI Corporation's Multikine has been granted a waiver by the UK's MHRA, exempting it from pediatric evaluation for head and neck cancer treatment. This regulatory decision could expedite the product's market entry in the UK.
The waiver from the MHRA means CEL-SCI can bypass pediatric trials for Multikine, potentially accelerating its approval process in the UK. This is a positive regulatory development, likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100